Illustrative stock photograph, not a Diva client, a diagnosis or a treatment result. The person pictured is not identified as having acne or pigmentation concerns. Photo: Andrea Piacquadio / Pexels. No endorsement is implied.
The bump has flattened. It no longer feels tender. Yet, in the mirror, a brown mark seems to be keeping its appointment long after the breakout has left.
In that imagined moment, the temptation is understandable: scrub a little harder, add another serum, find the product that promises a faster reset. But the colour left after inflammation is not dirt, and treating it as something to scour away can create another problem.
Post-inflammatory hyperpigmentation, often shortened to PIH, is one reason a breakout can remain visible after the original spot settles. Understanding it changes the question from “How do I erase this immediately?” to “What is this mark, what is keeping it going, and what could help without causing more irritation?”
This article is adult skin education, not a diagnosis from a photograph or a prescription. Its focus is the quieter stage after a breakout: the different kinds of marks people call scars, the limits of treatment research, and the value of a plan that respects the skin rather than punishing it.
A mark and a scar are different problems
People often use “acne scar” to describe anything visible after a pimple. Clinically, that can mix together different changes.
A flat patch of altered colour is not the same as a depression or a raised area in the skin. Acne scars involve changes in texture or structure. Pigment changes can exist without those changes, and a person can also have both at once. The American Academy of Dermatology’s guide to acne-scar signs explains why a flat mark is usually not a scar.
There is another distinction within colour changes. Brown or darker pigment-related marks are different from persistent redness, often called post-inflammatory erythema. The two can coexist, and their appearance varies with skin tone and lighting. A mirror, phone camera or colour chart cannot reliably sort out every case.
This is why a product described as “for acne scars” can be a confusing starting point. Is it intended to address colour, texture, active acne, or several things? A useful consultation makes those targets clear before discussing a treatment.
You do not have to learn every medical term. You should be able to ask what problem a proposed product or procedure is actually intended to treat.
Why the colour can outlast the breakout
Inflammation or injury can stimulate extra melanin production and alter where that pigment is deposited in the skin. Melanin is the pigment involved in normal skin colour. In PIH, the visible change follows a local event such as acne, eczema, irritation or an injury.
The pigment may be in more superficial or deeper skin layers, which helps explain why marks do not all behave alike. PIH can occur in any skin tone, but it is often more pronounced and persistent in darker skin. DermNet’s dermatologist-reviewed explanation describes the mechanism and the importance of a history and examination.
None of this means that naturally darker skin needs correcting. The subject is an acquired change that someone may or may not want to address, not a preferred shade of skin.
Nor does the location of a brown patch automatically prove that acne caused it. Melasma, for example, is a different pigment condition that commonly creates facial patches and may be associated with hormonal changes and sunlight. The AAD’s melasma overview explains that separate diagnosis.
The timeline matters. A clinician may ask what was there before the mark, what you applied, whether it itches or changes, and whether new spots are still appearing. Those ordinary details can be more useful than the name of the latest “brightening” ingredient.
There are two clocks running
An inflamed spot and the pigmentation that follows it do not necessarily settle on the same schedule. One can improve while the other remains visible.
The AAD notes that, after the trigger has stopped, a mark a few shades darker than the surrounding skin may fade over six to twelve months. Deeper pigment can take longer. That is a broad guide, not a countdown for an individual face. Its dark-spot guidance also emphasises finding and addressing the cause.
This distinction helps make sense of an apparently contradictory experience: fewer new breakouts, but still many visible marks. That does not automatically mean the acne treatment has failed. The active condition and the leftover colour may need to be assessed separately.
Equally, waiting is not the right response to every unfamiliar spot. The idea of slow fading applies to a correctly identified condition, not to a mark whose cause is uncertain or whose behaviour is changing.
A sensible review asks what has changed, what has not, and whether the original explanation still fits. It does not simply extend the waiting period forever.
The problem with fighting a mark too hard
There is a particular frustration in buying something to improve the skin and finding that it stings, peels or leaves another patch. Irritation can become part of the same cycle that produced the original concern.
For acne-prone skin, the AAD’s advice for darker skin tones favours gentle care and avoiding actions such as picking or harsh scrubbing. This is not an argument against effective acne treatment. It is a reminder that tolerability belongs in the plan.
Imagine changing a cleanser, exfoliant and treatment serum in the same week. If the skin reacts, it becomes difficult to work out which change mattered. That hypothetical example is a reason to discuss a manageable routine, rather than a rule that one particular number of products suits everyone.
Burning is not a useful badge of commitment. If a prescribed treatment irritates, contact the prescriber or pharmacist about what to do rather than guessing at a stronger routine. If an unprescribed cosmetic repeatedly causes discomfort or a rash, do not keep applying it merely because the packaging calls the sensation “working.”
A good plan should explain what reactions are expected, what is not acceptable, and who to contact. That is more useful than a promise to be “gentle” with no further detail.
Treating new acne and treating old marks are connected
It is easy to focus on the oldest, darkest mark while new inflamed spots keep arriving. But a plan that only targets colour may leave the source of new marks untouched.
Acne care and pigment care are therefore related questions, not necessarily two separate shopping lists. Some treatments may be considered for both concerns, while others address one more directly. The choice depends on the diagnosis, the pattern of acne, skin tolerance and individual circumstances.
This is also why “post-inflammatory” should not be read as a guarantee that all inflammation has ended. There may be old marks and active acne on the same face. The useful objective is not just to inspect yesterday’s spot, but to understand the pattern producing tomorrow’s.
For someone with repeated painful breakouts, scarring, persistent irritation or significant distress, professional assessment may be more useful than adding another fading product. Skin concerns do not have to become severe enough for other people to notice before they deserve attention.
The goal of that assessment is a workable explanation and plan. It should not assume that everybody wants the same appearance or has the same budget, tolerance for treatment or time available.
What controlled treatment studies actually tell us
There is research behind some treatments for PIH. The question is how far each study can reasonably take us.
An older randomized trial studied topical tretinoin against its vehicle, the preparation without the active drug, in Black patients with PIH. Fifty-four participants completed the forty-week study. The treated facial lesions became lighter than those in the comparison group. The 1993 New England Journal of Medicine study record reports those results.
That is evidence for a particular treatment under study conditions, not a claim that every cosmetic labelled “retinol” will do the same thing. The trial is also old and relatively small. Ingredient family names do not make different formulations interchangeable.
A more recent randomized, double-blind trial examined azelaic-acid gel for acne-related pigmentation and redness. Seventy-two people entered and sixty completed twelve weeks. The researchers reported improvements in pigment measurements, including between-group differences at the end of the study. However, the completers were aged eighteen to thirty-three, and nearly all had Fitzpatrick skin type III, with only two type IV. This was not a broad sample of every skin tone.
Importantly, twenty of the thirty participants in the active-treatment group reported mild irritation symptoms. No serious adverse events were reported. The full 2024 trial makes clear why an encouraging result should not be rewritten as “irritation-free.”
Neither example is a recommendation to copy a study regimen. They show why it is worth asking about both benefit and tolerability, and whether the people and product studied resemble the situation being discussed.
Why a review is not a league table of treatments
A systematic review can bring a scattered literature into view, but it cannot make unlike studies identical.
A systematic review published in July 2026 brought together fifty papers reporting fifty-one studies and 1,868 patients. Its searches covered publications through July 2025. The evidence varied enough that an effect-size meta-analysis was not feasible. Outcomes, adverse-event reporting and representation of different skin phototypes were inconsistent. The review by Chow and colleagues supports considering pigmentation alongside active acne, without establishing one universally best treatment.
A percentage from one small study should not be placed next to a percentage from another and treated as a fair contest. Were they measuring the same kind of mark? Was “improvement” assessed the same way? Were the follow-up periods similar? Did people stop because of irritation?
Representation matters too. A broad label such as “skin of colour” does not tell us which skin tones or populations were actually included. Readers deserve that detail, especially when the treatment itself can affect pigmentation.
Evidence can support a careful discussion without supporting a ranking, a guarantee or a one-size-fits-all package.
A procedure is not automatically a shortcut
A peel or light-based treatment may sound more decisive than waiting for a topical plan. The difficulty is that a procedure can itself cause inflammation or injury, which may worsen pigmentation in susceptible skin.
That does not mean every procedure is inappropriate. It means assessment, selection and the practitioner’s experience matter. DermNet discusses both potential benefit and the risk of aggravating PIH.
Before agreeing to a procedure, reasonable questions include: What exactly are we treating? What evidence supports this option for my type of mark? What is the risk of darker or lighter patches? What aftercare and follow-up are included? What happens if there is no improvement or a complication?
A treatment name on a service menu cannot answer those questions by itself. Nor does the evidence for one device, setting or patient group establish the result of a different protocol.
Home experiments with concentrated peels are not an equivalent substitute for assessment and appropriately supervised care. Faster is not better if the result is another injury to manage.
Sun protection supports the plan, but does not diagnose the mark
Sunlight can darken pigmentation, so protection is part of managing exposed skin rather than an optional finishing touch. The AAD’s dark-spot guidance recommends broad-spectrum, water-resistant SPF 30 or higher and notes the role of iron oxide in tinted sunscreens for protection against visible light.
Shade and protective clothing remain useful alongside sunscreen. Choose a product you can use as directed; a tint should be wearable, not another obstacle. AAD guidance on dark spots and sun protection.
This is supporting care, not a promise that sunscreen alone will erase a particular mark. It also does not tell you whether the mark is PIH, melasma or something else. Protection and diagnosis answer different questions.
Be wary of mystery “lightening” products
A small unlabelled pot, an imported mixture with an incomplete ingredient list, or a promise of rapid permanent lightening deserves caution. You cannot judge safety from the speed of a visible change.
The World Health Organization warns about mercury-containing skin-lightening products. These products can be hazardous to health. This is a reason to question an unknown mixture, not to assume that every product without a familiar brand contains mercury. Appearance, smell and a seller’s reassurance are not reliable substitutes for knowing what is in a product.
Unknown mixtures should not be confused with a properly prescribed medicine used for a defined purpose under supervision. The label, origin, intended use and professional guidance all matter. Ask a South African pharmacist or dermatologist about local suitability rather than assuming an online seller’s claims establish it.
Household bleach does not belong on the skin as a treatment for marks. “Natural” is not a safety test either. A kitchen ingredient and a tested formulation are not the same thing, and an unfamiliar reaction is not evidence that a remedy is removing pigment successfully.
Progress should not require a daily interrogation of your face
A close-up phone image in harsh light is not a neutral report card. Different lighting, angles, exposure and filters can make comparisons misleading. If photographs are part of an agreed review, keeping the conditions similar makes the record more useful.
It can also help to separate the questions. Are there fewer new inflamed spots? Is the skin tolerating the plan? Are established marks changing? Is the routine affordable and manageable? Those are more informative than asking whether the whole face looks “perfect” today.
You may choose makeup or other camouflage while considering treatment, or decide not to pursue pigment treatment at all. Neither choice needs defending. It is possible to care about a skin concern without making its disappearance a condition for feeling presentable.
A useful plan leaves space for ordinary life. It does not require constant product changes, daily magnification or the belief that a visible mark means you have failed at self-care.
Know when to have a mark examined
Do not assume every unfamiliar or changing dark spot is a leftover breakout. A growing or bleeding spot, a sore that does not heal, or a concerning change in colour, shape or sensation deserves medical assessment rather than an attempt to fade it first.
The AAD’s guidance on recognising skin cancer in darker skin tones is a reminder that assessment matters across skin tones. This does not mean ordinary PIH turns into cancer. It means an uncertain diagnosis should not be hidden behind a cosmetic treatment.
Bring the history and the products you use to the appointment, including medicines and anything bought online. Mention pregnancy, plans for pregnancy or breastfeeding, as these can affect treatment choices. Ask what would count as improvement and when the plan should be reviewed.
The best outcome of a consultation may be clarity before it is a prescription.
Frequently asked questions
Is the dark mark proof that the pimple is still there?
Not necessarily. A flat pigment change can remain after an inflamed spot settles. However, old marks and active acne can exist together, so the appearance of one patch does not describe everything happening in the skin. If the area remains painful, raised, itchy or otherwise changes, have it assessed rather than assuming it is only leftover colour.
Will every mark disappear completely?
No treatment or timeline can guarantee that. The cause, depth of pigment, continuing inflammation and individual response all matter. Many marks fade, but progress varies. A review should consider whether the diagnosis is right and whether the plan is helping, rather than promising that everyone will reach the same endpoint by a particular date.
Should I exfoliate until the colour comes off?
No. Pigment is not a surface stain to scrub away. Aggressive scrubbing or repeated irritation can create more inflammation and potentially more discoloration. That does not mean every exfoliating ingredient is unsuitable; it means selection and tolerability matter. Ask for a clear plan rather than combining strong products in an attempt to accelerate the result.
Are a scar cream and a dark-spot product interchangeable?
Not automatically. A change in skin texture and a flat colour change are different targets, even if both followed acne. Marketing names can blur that distinction. Ask which concern the product is intended to address, what evidence supports the claim, and how it fits with any ongoing acne treatment.
Can I use a study’s treatment during pregnancy?
Do not assume that you can. The European Medicines Agency advises against topical retinoid medicines during pregnancy or when planning pregnancy. Discuss suitable alternatives with your clinician or pharmacist. Breastfeeding also needs an individual suitability check. An adult treatment trial is not a pregnancy-safety study, and these summaries are not instructions to copy the tested regimens.
Does choosing not to treat the marks harm my skin?
Once a clinician has identified a harmless pigment change and any active condition is appropriately managed, cosmetic fading is a personal choice. You may prefer treatment, camouflage or no pigment-focused intervention. The important distinction is between choosing not to pursue a cosmetic goal and leaving an unexplained or changing lesion unexamined.
Educational information for adults, not an individual diagnosis or treatment prescription. Sources checked on 9 November 2026. Appropriate clinical review is recommended before publication.